23:48 , Aug 13, 2019 |  BC Extra  |  Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

Pharming licenses Novartis autoimmune candidate  Pharming Group N.V. (Euronext:PHARM) gained rights to PI3Kδ inhibitor CDZ173 from Novartis AG (NYSE:NVS; SIX:NOVN) for patients with activated PI3Kδ syndrome, a primary immune deficiency. Novartis will receive $20 million...
21:29 , Jul 18, 2019 |  BC Innovations  |  Finance

As funding dwindles, CIRM believes goals within reach

If the California Institute for Regenerative Medicine is unable to obtain funding to continue operations when its current reserves run out, the organization still believes the relatively modest goals set forth in its five-year plan...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
21:00 , Jun 7, 2018 |  BC Extra  |  Company News

BrainStorm considering right to try for ALS therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is considering offering NurOwn to treat amyotrophic lateral sclerosis under the recently enacted federal right-to-try law, BrainStorm President and CEO Chaim Lebovits told BioCentury. He also discussed the company’s plans...
19:17 , Apr 13, 2018 |  BC Week In Review  |  Company News

CIRM launches industry partnership network for its stem cell projects

The California Institute for Regenerative Medicine (CIRM) launched its Industry Alliance Program (IAP) to secure industry partnerships and funding for its stem cell research projects. IAP will connect pharma, biotech and VC firms with CIRM-funded...
02:52 , Dec 8, 2017 |  BC Week In Review  |  Company News

CIRM awards $20M grant to Poseida

The California Institute for Regenerative Medicine (CIRM) awarded $20 million to Poseida Therapeutics Inc. (San Diego, Calif.) to assess the safety and efficacy of its lead candidate P-BCMA-101 in a Phase I study to treat...
04:51 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

BrainStorm starts Ph III of NurOwn to treat ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) began a Phase III trial of NurOwn (MSC-NTF cells) to treat amyotrophic lateral sclerosis (ALS). The double-blind, placebo-controlled, U.S. study will enroll about 200 patients. The primary endpoint is safety,...
22:52 , Sep 28, 2017 |  BC Extra  |  Company News

CIRM names CEO, funds additional clinics and trials

California Institute for Regenerative Medicine named Maria Millan CEO and president. She was interim CEO and president and VP of therapeutics, and will succeed President Randal Mills, who left in June. CIRM also said it...
21:28 , Jul 28, 2017 |  BC Week In Review  |  Company News

BrainStorm receives $15.9M CIRM grant

The California Institute for Regenerative Medicine (CIRM) awarded BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) $15.9 million to fund a Phase III trial of NurOwn to treat amyotrophic lateral sclerosis. BrainStorm said it is in "advanced stages"...
22:31 , Jul 21, 2017 |  BC Extra  |  Financial News

CIRM grants BrainStorm $15.9M for ALS trial

The California Institute for Regenerative Medicine (CIRM) awarded BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) $15.9 million to fund a Phase III trial of NurOwn to treat amyotrophic lateral sclerosis. BrainStorm said it is in "advanced stages"...